Citadel Advisors’s IGM Biosciences IGMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-26,800
Closed -$30.8K 13691
2025
Q1
$30.8K Sell
26,800
-12,300
-31% -$22.9K ﹤0.01% 12794
2024
Q4
$239K Buy
39,100
+17,600
+82% +$209K ﹤0.01% 10123
2024
Q3
$356K Buy
21,500
+12,000
+126% +$131K ﹤0.01% 8957
2024
Q2
$65.3K Sell
9,500
-500
-5% -$4.28K ﹤0.01% 11453
2024
Q1
$96.5K Sell
10,000
-1,100
-10% -$12.7K ﹤0.01% 11413
2023
Q4
$92.2K Sell
11,100
-800
-7% -$4.64K ﹤0.01% 11033
2023
Q3
$99.4K Sell
11,900
-9,900
-45% -$84K ﹤0.01% 10903
2023
Q2
$201K Buy
21,800
+18,900
+652% +$212K ﹤0.01% 9877
2023
Q1
$39.8K Sell
2,900
-8,800
-75% -$182K ﹤0.01% 12438
2022
Q4
$199K Buy
+11,700
New +$234K ﹤0.01% 10151
2022
Q2
Sell
-69,200
Closed -$1.85M 13430
2022
Q1
$1.85M Buy
69,200
+60,000
+652% +$1.12M ﹤0.01% 6254
2021
Q4
$270K Sell
9,200
-36,000
-80% -$1.79M ﹤0.01% 11145
2021
Q3
$2.97M Buy
45,200
+35,100
+348% +$2.69M ﹤0.01% 5386
2021
Q2
$840K Sell
10,100
-5,900
-37% -$437K ﹤0.01% 8802
2021
Q1
$1.23M Sell
16,000
-15,300
-49% -$1.39M ﹤0.01% 7588
2020
Q4
$2.76M Buy
31,300
+20,600
+193% +$1.45M ﹤0.01% 4716
2020
Q3
$790K Buy
+10,700
New +$633K ﹤0.01% 6454

Other funds holding IGMS

Citadel Advisors's IGMS Position: Q3 2024 in Review

Citadel Advisors sold out of IGM Biosciences (IGMS) in Q3 2024, closing a stake of 1,979 shares — an estimated $21.7K sold.

Citadel Advisors first reported a position in IGMS in Q3 2019 and held it in 18 quarters. The position peaked at $3.78M in Q4 2020. 72 funds tracked by Wall St. Rank hold IGMS as of Q3 2024.

  • Citadel Advisors reported no remaining IGM Biosciences position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,979 IGM Biosciences shares in Q3 2024, an estimated $21.7K.
  • Citadel Advisors first reported a position in IGM Biosciences in Q3 2019 and held it in 18 quarters.
  • Citadel Advisors's IGM Biosciences position peaked at $3.78M in Q4 2020.
  • 72 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.